Previous 10 | Next 10 |
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced the appointment of Howard J. Franklin, MD, as Se...
Summary Assertio is a truly impressive turnaround story that is now set to grow, mostly through M&A. The crucial ingredient is the digital-only sales model, which puts acquired drugs on a much lower cost basis while maintaining sales. The company can rinse-repeat this as they ha...
Summary Q4 preliminary results illustrate the best product sales quarter for the past 5 years. Technicals, valuation, and profitability trends all point to rising prices for the stock. An aggressive covered call strategy is an excellent play here for both income and capital apprecia...
Assertio ( NASDAQ: ASRT ) entered into separate, privately negotiated exchange agreements with a limited number of holders of Assertio's currently outstanding 6.50% Convertible Senior Notes due 2027. Post the exchange agreements, the company will exchange $30M principal amoun...
LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced it has entered into separate, privately negotiated exchange agreements (the ...
Assertio ( NASDAQ: ASRT ) has reported prelim net product sales of $49M-$50M (vs. $46.90M estimated ) for its fourth quarter, representing an year-over-year growth of at least 54%. This also marks the drugmaker's highest quarter of net product sales in the past five years. Q4 ...
Year-over-Year Net Product Sales Increased at Least 54% for the Fourth Quarter and 41% for the Full Year Cash Flows from Operations Was at Least $26 Million for the Fourth Quarter and $78 Million for the Full Year To Report Fourth Quarter and Audited Full Year 2022 Financial Res...
LAKE FOREST, Ill., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that Dan Peisert, CEO, and Paul Schwichtenberg, C...
NEW YORK, NY / ACCESSWIRE / February 14, 2023 / Sidoti & Company, LLC announces that its two spring conferences are now open for registration. The March Virtual Small-Cap Conference will take place on Wednesday and Thursday, March 22-23, 2023, and the May Virtual Micro-Cap Conference wil...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s been a few months since I last wrote about the best penny stocks . It’s never an easy task finding quality companies with rock-bottom prices under $5. In the past, I’ve limited my search...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will rel...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...